Price History

Hover for the daily close. The dotted line marks the period open.

Compare EDSA with… →

EDSA Key Statistics

As of Sep 4, 2026

Trading

Open: $4.72
Previous Close: $4.76
Day's Range: 4.72–4.97
52-Week Range: 0.72–20.32
Volume: 36.40K
Beta: 1.06

Valuation

Market Cap: $45.60M
P/E Ratio: unprofitable
EPS (ttm): −1.72

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$7.19M
Profit margin: 0.00%
Shares Outstanding: 9.64M
1-Year Return: +86.96%

Dividend and dates

Avg Volume: 105.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EDSA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−83.95%+233.10%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+233.10%
2025	−15.48%
2024	−63.24%
2023	−69.78%
2022	−61.63%
2021	+32.47%
2020	+3.66%
2019	−24.91%
2018	−83.95%
2017	−60.10%
2016 (partial year)	−30.95%

As of September 4, 2026.

EDSA Revenue and Earnings by Fiscal Year

FY ends September

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$7.19M	—
2024	$0.00	−$6.17M	—
2023	$0.00	−$8.37M	—
2022	$0.00	−$17.55M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$7.13M	−$7.19M	—
2024	$0.00	—	−$6.32M	−$6.17M	—
2023	$0.00	—	−$8.64M	−$8.37M	—
2022	$0.00	—	−$17.59M	−$17.55M	—

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

EDSA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	EDSA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Edesa Biotech, Inc. (EDSA) carries a market capitalisation of $45.60M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 17.

The most recent close on file for EDSA is $4.73, dated September 4, 2026. That is −$0.03 (−0.63%) against the previous close. The 52-week range on file runs from $0.72 to $20.32. The latest close sits 556.94% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $7.19M. Profit margin runs at 0%. Trailing earnings per share are −1.72.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.06. Daily returns over the trailing 10 years annualize to a volatility of 124.31%. The trailing one-year price return is +86.96%. Measured over 10 years, that is −39.91% a year compounded.

Growth & Income

No dividend is on file for EDSA.

So far in 2026 the price is +233.10%. The strongest complete calendar year on file is 2021 at +32.47%; the weakest is 2018 at −83.95%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Edesa Biotech, Inc. (EDSA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Edesa Biotech, Inc.	EDSA	$45.60M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Edesa Biotech, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Edesa Biotech, Inc.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Visit website →

Edesa Biotech, Inc. (EDSA) Stock Analysis